Prime Medicine - PRME Income before deduction of interest, taxes and amortization
How do strategic platform licensing alliances impact the development of Prime Medicine, Inc. (PRME)? Strict FDA oversight and high development costs are constraining growth. Process optimization through manufacturing outsourcing allows the company to focus on science, as confirmed by the total EBITDA for the period. The parameter value reaches 0.00, demonstrating the current operational efficiency of the business in monetary terms.
Prime Medicine (PRME) - metric breakdowns and financial figures
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- debt level and financial liquidity data:
Debt to Equity Ratio Prime Medicine, Inc.|PRME - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Prime Medicine Inc|PRME - Company Aggregate Debts|Debt to Book Value Prime Medicine|PRME - Company Long-Term Debts|Short-Term Debt Volume Prime Medicine|Immediate Liquidity Ratio primemedicine.com
- earnings and multiples data:
PRME - Net Profit|Expected Net Profit Prime Medicine, Inc.|PRME - Price to Earnings Ratio|Future Price to Earnings Multiple primemedicine.com|PRME - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Prime Medicine|PRME - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Prime Medicine|PRME - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months primemedicine.com|PRME - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Prime Medicine, Inc.
- sales revenue and business income indicators:
Summary company analytics:PRME - Prime Medicine Bio
The complex logistics of temperature corridors for Prime Medicine (PRME) gene therapies directly impact operating expenses. EBITDA reflects the business's ability to generate profit before interest and taxes. This metric excludes the impact of depreciation and amortization, focusing instead on the efficiency of core production. Growth in this indicator confirms resilience against supply costs. It is critical for investors to correlate this trend with the debt load to assess real liquidity.
Who Prime Medicine, Inc. competes with
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Avidity Biosciences Inc|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization GeneDx Corp WGS|Operating profit EBITDA RARE|beamtx.com - Operating profit before amortization|Operating profit EBITDA SRPT (Sarepta)|Operating income before deduction of amortization Twist Bioscience Inc (TWST)|10x Genomics Corp - Operating profit EBITDA|Intellia Corp (NTLA) - Operating profit before deduction of amortization|STOK: Operating profit EBITDA|BLFS - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Wave Life Sciences Ltd.|Operating profit before amortization MAZE (Maze Therapeutics, Inc.)|Operating profit EBITDA SION|TSHA - Profit before interest, taxes and amortization|uniQure N.V. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization MGTX|REGENXBIO - Operating profit EBITDA|Operating income before deduction of amortization Solid Biosciences Inc SLDB|Ocugen Corp (OCGN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization PACB|BNTC (Benitec Biopharma Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization designtx.com (DSGN)|Operating profit before deduction of amortization RCKT (Rocket Pharmaceuticals, Inc.)|Operating income before deduction of amortization 4DMT|Profit before payment of interest, taxes and amortization Lexeo Therapeutics, Inc. LXEO|KRRO (Korro Bio Inc.) - Profit before deduction of interest, taxes, depreciation and amortization|EDIT - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization SLN (silence-therapeutics.com)|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Codexis|SGMO (Sangamo) - Operating profit EBITDA|Profit before interest, taxes and amortization Nautilus Biotechnology Inc NAUT|Operating profit EBITDA MGX|precisionbiosciences.com - Operating profit before amortization|Profit before payment of interest, taxes and amortization Generation Bio GBIO|BOLD: Operating profit before amortization|Exicure Corp - Operating profit EBITDA|IMNN - Operating profit EBITDA|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization MBIO (Mustang Bio)|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|BNGO: Income before deduction of interest, taxes and amortization|Operating profit EBITDA APDN|Operating income before deduction of amortization bluebird bio, Inc|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|OMGA - Operating profit before deduction of amortization|Singular Genomics - Operating profit EBITDA|Profit before interest, taxes and amortization Regulus Therapeutics, Inc.|SYRS (Syros) - Operating profit before deduction of amortization|Telesis Bio, Inc - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before deduction of amortization unitybiotechnology.com (UBX)
